Priority 1 from the Living With and Beyond Cancer PSP

UNCERTAINTY: What are the best models for delivering long-term cancer care including screening, diagnosing and managing long-term side effects and late-effects of cancer and its treatment (e.g. primary and secondary care, voluntary organisations, self-management, carer involvement, use of digital technology, etc)? (JLA PSP Priority 1)
Overall ranking	1
JLA question ID	0073/1
Explanatory note	Not available for this PSP
Evidence	None identified
Health Research Classification System category	Cancer

Extra information provided by this PSP
Original uncertainty examples	For some people, newer medicines mean that cancers and leukaemias are treated more like a chronic disease now, so what's the best way for them to get their healthcare - do they always need to see a specialist or can follow ups be done at their GPs surgery? ~ What is the role of community pharmacy in supporting patients living with and beyond cancer with their medicines? ~ How well are we supporting AYA patients treated for Hodgkin's Lymphomas in the 1980s, who are now facing late effects and second cancers as a result of their treatment? Can anything be done to reduce their considerable risks? ~ How do CCGs, Secondary Care, Primary Care, Community sector and voluntary sector work better together to give cohesive support to those living with and beyond cancer? Especially when there are competing priorities for funding and resources. ~ Appropriate methods to deliver long-term treatments (e.g. 10 years of endocrine treatment for breast cancer) with minimum disruption to everyday life.
Submitted by	Individual survey submissions categorised by Healthcare professional, Patient, Relative/Carer, Other, and Unknown. For full details of the type of submitter for each individual question, please see the spreadsheet of data held on the JLA website.

Extra information provided by this PSP

Original uncertainty examples

For some people, newer medicines mean that cancers and leukaemias are treated more like a chronic disease now, so what's the best way for them to get their healthcare - do they always need to see a specialist or can follow ups be done at their GPs surgery? ~ What is the role of community pharmacy in supporting patients living with and beyond cancer with their medicines? ~ How well are we supporting AYA patients treated for Hodgkin's Lymphomas in the 1980s, who are now facing late effects and second cancers as a result of their treatment? Can anything be done to reduce their considerable risks? ~ How do CCGs, Secondary Care, Primary Care, Community sector and voluntary sector work better together to give cohesive support to those living with and beyond cancer? Especially when there are competing priorities for funding and resources. ~ Appropriate methods to deliver long-term treatments (e.g. 10 years of endocrine treatment for breast cancer) with minimum disruption to everyday life.

Submitted by

Individual survey submissions categorised by Healthcare professional, Patient, Relative/Carer, Other, and Unknown. For full details of the type of submitter for each individual question, please see the spreadsheet of data held on the JLA website.

PSP information
PSP unique ID	0073
PSP name	Living With and Beyond Cancer
Total number of uncertainties identified by this PSP.	54 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website)
Date of priority setting workshop	11 June 2018